Tuberculosis is preventable through a combination of vaccination, screening, treatment of latent infections, and basic public health measures. No single intervention eliminates the risk entirely, but layering these strategies together dramatically reduces the chances of getting TB or spreading it to others. The World Health Organization has set a target of reducing new TB cases by 80% by 2030, a goal built on the premise that most TB is, in fact, avoidable.
How the BCG Vaccine Protects Against TB
The BCG vaccine is the only approved vaccine against tuberculosis and has been in use since the 1920s. It works best when given to infants and young children, which is why most countries with high TB rates include it in their childhood immunization schedules. In a long-term follow-up study of nearly 2,800 people vaccinated as children, BCG reduced the overall rate of TB by about 52%. Protection was even stronger against TB that spreads beyond the lungs, with a 63% reduction in those cases.
One important finding from that study: protection lasted for decades. Vaccine efficacy held steady at around 54% to 62% through the first three decades after vaccination, dipping in the fourth decade before rebounding. This challenges the older assumption that BCG wears off after 10 to 15 years.
BCG does have real limitations. Its effectiveness against pulmonary TB in adults varies widely depending on geography, and it does not reliably prevent infection itself. It reduces the severity of disease and the risk of life-threatening forms of TB in children, but it is not a complete shield. Most high-income, low-burden countries like the United States do not routinely use it.
Catching and Treating Latent TB Before It Becomes Active
About a quarter of the world’s population carries latent TB infection, meaning the bacteria are present in the body but dormant. A person with latent TB feels perfectly healthy, cannot spread the disease, and may never develop symptoms. But there is a 5% to 10% lifetime risk that latent TB will “wake up” and become active disease. Half of that risk plays out in the first two years after infection, with the remainder spread across the rest of a person’s life.
This is where preventive treatment makes a major difference. Across a large meta-analysis of contact tracing studies, preventive therapy reduced the risk of developing active TB by about 49% overall. Among people who tested positive for latent TB on a blood or skin test, the protection was far more dramatic. Children under 5 saw a roughly 91% reduction in risk, adolescents aged 5 to 17 saw about 80%, and adults 18 and older saw around 83%.
Treatment regimens have gotten shorter and more convenient over the years. The CDC now recommends short-course options over the older approach of taking a single drug daily for six to nine months. Current preferred regimens include:
- 3 months, once weekly (two drugs combined): This 12-dose regimen is recommended for most people aged 2 and older, including many people living with HIV.
- 4 months, daily (one drug): Recommended for children and adults who are HIV-negative, and a good option for people who cannot tolerate the standard drug or were exposed to a drug-resistant strain.
- 3 months, daily (two drugs combined): Another short-course option for both children and adults.
- 1 month, daily (two drugs combined): The newest and shortest regimen, recognized by the WHO as an alternative for people living with HIV.
The older six- or nine-month regimens using a single daily drug are still effective but are now considered backup options. Shorter courses have comparable effectiveness with better completion rates, since fewer people drop out before finishing.
Who Should Be Screened
Screening for latent TB is targeted rather than universal. The groups prioritized for testing include people who have been in close contact with someone who has active TB, people living with HIV, organ transplant recipients, people with end-stage kidney disease, and anyone starting medications that suppress the immune system. Pregnant and breastfeeding patients who fall into a high-risk group also need careful evaluation, though treatment timing may be adjusted.
Two types of tests are used: the tuberculin skin test (TST), which involves injecting a small amount of protein under the skin and checking for a reaction 48 to 72 hours later, and blood-based tests called interferon-gamma release assays (IGRAs). A 2024 study of over 22,000 participants found that IGRAs were significantly better at predicting who would actually go on to develop active TB. Current guidelines from the CDC, the American Thoracic Society, and the Infectious Diseases Society of America all prefer IGRAs over the skin test for most screening situations, though skin tests are still used when blood tests are not available.
Nutrition and Living Conditions Matter
TB is often described as a disease of poverty, and the data backs that up. Undernutrition is one of the most significant drivers of the TB epidemic worldwide. It increases vulnerability to developing active disease, worsens treatment outcomes, and raises the risk of death. The relationship runs in both directions: TB itself causes weight loss and malnutrition, which further weakens the body’s ability to fight the infection.
In 2025, the WHO released new guidelines specifically recommending food assistance for household contacts of TB patients in food-insecure settings. This recommendation was informed by the RATIONS trial, which studied whether improving nutritional status in close contacts could reduce their risk of developing active TB. The finding was clear enough to change global policy. Crowded housing, poor ventilation, and lack of access to healthcare all compound the nutritional risk. Addressing these social determinants is not a soft add-on to TB prevention; it is central to it.
Preventing Spread in Healthcare and Congregate Settings
TB spreads through the air when a person with active pulmonary TB coughs, speaks, or sings. The bacteria can linger in the air for hours, especially in enclosed spaces with poor ventilation. Hospitals, prisons, shelters, and long-term care facilities are particularly high-risk environments.
Prevention in these settings follows a three-tier approach. Administrative controls come first: identifying potentially infectious patients quickly, isolating them in dedicated rooms, and ensuring lab results come back fast. These measures are considered the most important layer because they reduce the chance of exposure in the first place.
Environmental controls form the second tier. These include ventilation systems that push contaminated air away from other people, specialized filtration that can capture TB-sized particles, and ultraviolet light systems that kill airborne bacteria. The third tier is personal respiratory protection, meaning fitted respirator masks (not standard surgical masks) worn by healthcare workers entering rooms with known or suspected TB patients.
For the general public, the practical takeaway is simpler. Good ventilation in indoor spaces reduces TB transmission risk. Opening windows in a room where someone is coughing does more than most people realize. In high-burden countries, improving airflow in homes, public transit, and workplaces is one of the most cost-effective prevention strategies available.
Why Prevention Still Falls Short
Despite all of these tools, TB killed roughly 1.25 million people in 2023. The gap between what is possible and what is happening comes down to implementation. Millions of people with latent TB are never tested. Many who are tested never start preventive treatment, and some who start do not finish. BCG coverage is inconsistent. Drug-resistant TB, which is harder and more expensive to treat, complicates prevention in some regions.
The WHO’s End TB Strategy envisions eliminating TB as a public health problem, defined as fewer than one case per million people. That goal requires not just medical tools but political will, sustained funding, and attention to the poverty and inequality that let TB persist. The disease is preventable in principle. Making it preventable in practice for everyone, everywhere, remains the harder problem.